CHUGAI PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1925-03-10
- Employees
- 7.6K
- Market Cap
- $83.6B
Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 127
- Registration Number
- NCT00144521
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
Phase 3
Completed
- Conditions
- Chemotherapy Induced Anemia
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 104
- Registration Number
- NCT00144495
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Phase 3
Completed
- Conditions
- Polyarticular Juvenile Idiopathic Arthritis
- Interventions
- Drug: MRA(Tocilizumab)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 19
- Registration Number
- NCT00144625
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: MRA (Tocilizumab)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 115
- Registration Number
- NCT00144534
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
Phase 3
Completed
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- Drug: MRA(Tocilizumab)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT00144612
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment
Not Applicable
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2008-12-15
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 14
- Registration Number
- NCT00144573
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
Not Applicable
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2008-12-15
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 31
- Registration Number
- NCT00144560
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
Phase 3
Completed
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- Drug: MRA(Tocilizumab)Drug: placebo
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 56
- Registration Number
- NCT00144599
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Phase 3
Completed
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- Drug: MRA(Tocilizumab)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 19
- Registration Number
- NCT00144664
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Phase 1
Completed
- Conditions
- Breast CancerHypercalcemia of MalignancyMetastatic CancerPain
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Chugai Pharmaceutical
- Registration Number
- NCT00060138
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States